Lucid Diagnostics (LUCD) Scheduled to Post Earnings on Wednesday

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) is scheduled to release its earnings data before the market opens on Wednesday, November 13th. Analysts expect Lucid Diagnostics to post earnings of ($0.18) per share for the quarter. Parties interested in participating in the company's conference call can do so using this link.

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.23) earnings per share for the quarter. The company had revenue of $0.98 million during the quarter. On average, analysts expect Lucid Diagnostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lucid Diagnostics Stock Up 4.0 %

LUCD traded up $0.04 during midday trading on Friday, hitting $1.04. 433,170 shares of the company were exchanged, compared to its average volume of 294,692. The firm's 50 day moving average price is $0.85 and its 200-day moving average price is $0.84. Lucid Diagnostics has a 1-year low of $0.63 and a 1-year high of $1.58. The firm has a market capitalization of $56.15 million, a P/E ratio of -0.85 and a beta of 1.41.

Analyst Ratings Changes

LUCD has been the topic of a number of recent analyst reports. Canaccord Genuity Group raised Lucid Diagnostics to a "strong-buy" rating in a research note on Tuesday, August 13th. Canaccord Genuity Group restated a "buy" rating and issued a $3.00 price target on shares of Lucid Diagnostics in a research report on Tuesday, August 13th. Ascendiant Capital Markets reduced their price objective on shares of Lucid Diagnostics from $7.50 to $7.25 and set a "buy" rating on the stock in a research note on Tuesday, September 10th. Finally, Needham & Company LLC reissued a "buy" rating and set a $2.50 target price on shares of Lucid Diagnostics in a research note on Tuesday, August 13th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Lucid Diagnostics currently has a consensus rating of "Buy" and a consensus target price of $3.94.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.